Which is better, LMAT or PRCT?

On the Buffett-Fit framework, LeMaitre Vascular, Inc. (LMAT) currently grades higher than PRCT — 77/100 (B grade) vs 27/100 (F). That said, "better" depends on which framework you trust — LMAT wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; PRCT wins on none. The full pillar breakdown is on this page.

Should I buy LMAT or PRCT?

This page is an educational comparison, not investment advice. Both LMAT and PRCT are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is LMAT better than PRCT for value investing?

On the Buffett-style value-investing framework, LMAT currently grades higher — 77/100 vs 27/100, a 50-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between LMAT and PRCT on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). LMAT currently scores 77/100 (B grade); PRCT scores 27/100 (F grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, LMAT or PRCT?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. LMAT and PRCT are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, LMAT or PRCT?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are LMAT and PRCT both Healthcare stocks?

Yes — both LeMaitre Vascular, Inc. (LMAT) and PROCEPT BioRobotics Corporation (PRCT) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this LMAT vs PRCT comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

LeMaitre Vascular

PROCEPT BioRobotics

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

PRCT

PROCEPT BioRobotics

Market cap

$1.65B

Sector

Healthcare

Overall winner

LeMaitre Vascular LMAT

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	LMAT	PRCT	Winner
Warren Buffett	77B	27F	LMAT
Benjamin Graham	89A	54D	LMAT
Philip Fisher	81C	52C	LMAT
Peter Lynch	67B	44D	LMAT
Joel Greenblatt	56D	0F	LMAT
Charlie Munger	68D	34F	LMAT
Terry Smith	69D	34F	LMAT

Side-by-side metrics

Metric	LMAT	PRCT
Market cap	$2.23B	$1.65B
P/E (TTM)	37.1x	-
EV/EBIT	36.6x	-
ROIC (TTM)	9.43%	-25.75%
Gross margin	72.39%	62.98%
Net margin	24.35%	-31.82%
Revenue CAGR 5y	12.75%	72.9%
EPS CAGR 5y	19.04%	-
Debt / Equity	0.5x	0.1x
Dividend yield	0.84%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

LMAT leads on

Net margin24.35%vs -31.82%+177%
ROIC (TTM)9.43%vs -25.75%+137%
Dividend yield0.84%vs 0.0%+100%
Market cap$2.23Bvs $1.65B+26%

PRCT leads on

P/E (TTM)-vs 37.1x+139%
EV/EBIT-vs 36.6x+134%
Revenue CAGR 5y72.9%vs 12.75%+83%
Debt / Equity0.1xvs 0.5x+68%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

LeMaitre Vascular

PROCEPT BioRobotics

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like LMAT

More like PRCT

Related on invest-like

Key terms in this analysis